Please login to the form below

Not currently logged in
Email:
Password:

dapagliflozin

This page shows the latest dapagliflozin news and features for those working in and with pharma, biotech and healthcare.

AZ’s Farxiga cuts risk of death in chronic kidney disease

AZ’s Farxiga cuts risk of death in chronic kidney disease

congress. In the DAPA-CKD trial, Farxiga (dapagliflozin) added to standard of care reduced the risk of cardiovascular or renal death and worsening of renal function by 39% compared to placebo

Latest news

More from news
Approximately 8 fully matching, plus 93 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...

Infographics